Understanding the metabolic profile of liver and pancreatic tumors
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors
This study is trying to find new ways to understand and treat liver and pancreatic tumors by looking at how these cancer cells use energy to grow.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Clichy) |
| Trial ID | NCT05794048 on ClinicalTrials.gov |
What this trial studies
This study aims to identify new prognostic and theranostic markers for hepatocellular carcinoma (HCC) and pancreatic tumors, including pancreatic adenocarcinoma and neuroendocrine tumors. It focuses on the metabolic reprogramming of cancer cells, which is crucial for tumor growth and proliferation. By analyzing the energy pathways involved in these tumors, the study seeks to improve patient management and treatment strategies based on more relevant biological markers. The research is conducted at Hôpital Beaujon in Clichy, France.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and over with either hepatocellular carcinoma or pancreatic tumors eligible for surgical treatment.
Not a fit: Patients with tumors that are not eligible for surgical intervention or those who do not meet the inclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with liver and pancreatic tumors.
How similar studies have performed: While metabolic profiling in cancer is an emerging field, this specific approach to hepatocellular carcinoma and pancreatic tumors is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria : Common criteria: * Patient aged 18 or over * Informed and having signed the consent to participate * Affiliated with a social security scheme or entitled 1- Patients with hepatocellular carcinoma * Having a HCC eligible for surgical treatment (liver resection or liver transplantation) not requiring preoperative anti-tumor treatment as validated by the multidisciplinary consultation meeting for primary hepatic tumors * OR having a HCC not eligible for curative treatment (liver resection, liver transplantation, tumor ablation), as validated by the multidisciplinary consultation meeting for primary hepatic tumors 2- Patients with pancreatic adenocarcinoma or pancreatic neuroendocrine tumor * Having ADKP or NET eligible for surgical treatment (duodenopancreatectomy, left pancreatectomy, enucleation, central pancreatectomy, hepatic metastasectomy) with or without preoperative anti-tumor treatment as validated by the multidisciplinary consultation meeting. * OR with an unresectable ADKP or TNEP, with only medical treatment plan as validated by the multidisciplinary consultation meeting Exclusion criteria : Criteria common to all patients: * Pregnancy and lactation * Lack of informed, written and signed consent * Adult person subject to a legal protection measure or unable to express consent * Patient under State Medical Aid (AME) * Person deprived of liberty by a judicial or administrative decision * Person undergoing psychiatric care 1- Patients with hepatocellular carcinoma * Suspicion of mixed tumor (hepatocholangiocarcinoma) or intrahepatic cholangiocarcinoma * History of systemic or locoregional anti-tumor treatment in the target tumor * Contraindication to a liver biopsy * Decompensated cirrhosis 2- Patients with pancreatic adenocarcinoma or pancreatic neuroendocrine tumor * Suspicion of mixed tumor (MINEN) or intra-pancreatic cholangiocarcinoma * Contraindication to a pancreatic / hepatic biopsy
Where this trial is running
Clichy
- Hôpital Beaujon — Clichy, France (Recruiting)
Study contacts
- Principal investigator: Valérie Paradis, MD, PhD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Valérie Paradis, MD, PhD
- Email: valerie.paradis@aphp.fr
- Phone: 01 40 87 54 63
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.